PASADENA, Calif.-(BUSINESS WIRE)---- Sarwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis's United States Patent No. 9,593,333 ("the '333 patent† ) is invalid and not infringed by Arrowhead's planned commercialization of investigational plozasiran, which is under FDA review. Arrowhead intends to vigorously. ...

Question-and-Answer SessionI'm sure we have a lot to talk about in terms of some of the updates from this week, but maybe just level set expectations in terms of what you see as the key priorities for the company right now.Dr. Christopher AnzaloneChairman, CEO & President Sure. We have a really busy 6 to 9 months ahead of us in essentially chronological order. I think what you're going to see is we will bring MAPT to the clinic. That's going to be our first CNS drug that is administered via a subcu injectio ...